Urinary tract infections (UTIs) are among the most common bacterial ailments treated in clinical practice globally, yet their frustrating tendency…
Read More
Pfizer and Astellas Secure FDA Priority Review for Perioperative Padcev and Keytruda Combination in Muscle-Invasive Bladder Cancer
The United States Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application (sBLA) from…
Read More
Macau Approves ImmunityBio’s Anktiva for Bladder Cancer, Marking First Asian Regulatory Milestone
ImmunityBio has achieved a significant regulatory victory with the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region, China,…
Read More
